From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer.

Published on Jan 28, 2020in Cells4.366
· DOI :10.3390/CELLS9020309
Chiara Bazzichetto9
Estimated H-index: 9
Fabiana Conciatori10
Estimated H-index: 10
+ 11 AuthorsMichele Milella50
Estimated H-index: 50
(University of Verona)
The threatening notoriety of pancreatic cancer mainly arises from its negligible early diagnosis, highly aggressive progression, failure of conventional therapeutic options and consequent very poor prognosis. The most important driver genes of pancreatic cancer are the oncogene KRAS and the tumor suppressors TP53, CDKN2A, and SMAD4. Although the presence of few drivers, several signaling pathways are involved in the oncogenesis of this cancer type, some of them with promising targets for precision oncology. Pancreatic cancer is recognized as one of immunosuppressive phenotype cancer: it is characterized by a fibrotic-desmoplastic stroma, in which there is an intensive cross-talk between several cellular (e.g., fibroblasts, myeloid cells, lymphocytes, endothelial, and myeloid cells) and acellular (collagen, fibronectin, and soluble factors) components. In this review; we aim to describe the current knowledge of the genetic/biological landscape of pancreatic cancer and the composition of its tumor microenvironment; in order to better direct in the intrinsic labyrinth of this complex tumor type. Indeed; disentangling the genetic and molecular characteristics of cancer cells and the environment in which they evolve may represent the crucial step towards more effective therapeutic strategies
📖 Papers frequently viewed together
52 Citations
4 Citations
#1Yaqing Zhang (UM: University of Michigan)H-Index: 17
#2Jenny Lazarus (UM: University of Michigan)H-Index: 7
Last. Marina Pasca di Magliano (UM: University of Michigan)H-Index: 31
view all 23 authors...
Regulatory T cells (Tregs) are abundant ion human and mouse pancreatic cancer. To understand the contribution to the immunosuppressive microenvironment, we depleted Tregs in a mouse model of pancreatic cancer. Contrary to our expectations, Treg depletion failed to relieve immunosuppression, and led to accelerated tumor progression. We show that Tregs are a key source of TGFβ ligands and, accordingly, their depletion reprogramed the fibroblast population, with loss of tumor-restraining, smooth mu...
67 CitationsSource
#1Christopher Nevala-Plagemann (UofU: University of Utah)H-Index: 3
#2Manuel Hidalgo (Cornell University)H-Index: 102
Last. Ignacio Garrido-Laguna (UofU: University of Utah)H-Index: 26
view all 3 authors...
Improvements in the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) have lagged behind advances made in the treatment of many other malignancies over the past few decades. For most patients with PDAC, cytotoxic chemotherapy remains the mainstay of treatment. For patients with resectable disease, modified 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) is the standard-of-care adjuvant therapy, although data from several randomized trials have shown improved ...
93 CitationsSource
#1Aurélien Marabelle (French Institute of Health and Medical Research)H-Index: 62
#2Dung T. Le (Johns Hopkins University)H-Index: 53
Last. Luis A. Diaz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 120
view all 22 authors...
PURPOSEGenomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that encode potential ne...
504 CitationsSource
#1Stefanie K. Wculek (Centro Nacional de Investigaciones Cardiovasculares)H-Index: 11
#2Francisco J. Cueto (Centro Nacional de Investigaciones Cardiovasculares)H-Index: 11
Last. David Sancho (Centro Nacional de Investigaciones Cardiovasculares)H-Index: 55
view all 6 authors...
Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better unders...
382 CitationsSource
#1Raffaela Santoro (University of Verona)H-Index: 10
#2Marco Zanotto (University of Verona)H-Index: 9
Last. Davide Melisi (University of Verona)H-Index: 31
view all 11 authors...
YAP and TAZ are central determinants of malignancy, however, their functions remain still undruggable. We identified TGFβ-activated kinase 1 (TAK1) as a central hub integrating the most relevant signals sustaining pancreatic cancer aggressiveness and chemoresistance. Glycogen synthase kinase (GSK)3 is known to stabilize TAK1, and its inhibition causes a reduction in TAK1 levels. Here, we hypothesized that TAK1 could sustain YAP/TAZ program, and thus, modulation of TAK1 expression through the inh...
19 CitationsSource
#1Yufan MaH-Index: 1
#2Yinquan PuH-Index: 1
Last. Xiaowei TangH-Index: 8
view all 7 authors...
Pancreatic duct adenocarcinoma (PDAC) is a highly malignant type of cancer with a low five-year survival rate. Gene alterations are crucial to the molecular pathogenesis of PDAC. Therefore, the present study analyzed gene expression profiles to reveal genes involved in the tumorigenesis of PDAC. A total of eight gene expression profiles (GSE15471, GSE16515, GSE41368, GSE62165, GSE62452, GSE71729, GSE71989 and GSE91035) and a PDAC dataset were acquired from the Gene Expression Omnibus and The Can...
6 CitationsSource
Tumor Associated Neutrophils (TANs) are recruited to the tumor microenvironment by cytokines and chemokines, can be classified according to their activation and cytokine status and effects on tumor cell growth in N1 and N2 TANs. N1 TANs exert an antitumor activity, by direct or indirect cytotoxicity. On the other hand, N2 TANs promote immunosuppression, tumor growth, angiogenesis and metastasis by DNA instability, or by cytokines and chemokines release. In tumor patients, either a high number of...
89 CitationsSource
#1Eileen M. O'Reilly (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 73
#2Do-Youn Oh (Seoul National University Hospital)H-Index: 56
Last. Philip A. PhilipH-Index: 76
view all 14 authors...
Importance New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination therapy in patients with mPDAC. Objective To evaluate the safety and efficacy of the anti–PD-L1 (programmed death-ligand 1) antibody using either durvalumab monotherapy or in combination with the anticytotoxic T-lymphocyte antigen 4 antibody using durvalumab plus tremelimumab therapy in patients with mPDAC. Design, Setting, and Part...
130 CitationsSource
#1Claudio Luchini (University of Verona)H-Index: 31
#2Nicola VeroneseH-Index: 69
Last. Aldo ScarpaH-Index: 99
view all 15 authors...
Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR−) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under...
19 CitationsSource
#1Claudio Luchini (University of Verona)H-Index: 31
#2Frédéric Bibeau (UNICAEN: University of Caen Lower Normandy)H-Index: 56
Last. Aldo Scarpa (University of Verona)H-Index: 99
view all 11 authors...
BACKGROUND: Cancers with a defective DNA mismatch repair (dMMR) system contain thousands of mutations most frequently located in monomorphic microsatellites and are thereby defined as having microsatellite instability (MSI). Therefore, MSI is a marker of dMMR. MSI/dMMR can be identified using immunohistochemistry to detect loss of MMR proteins and/or molecular tests to show microsatellite alterations. Together with tumour mutational burden (TMB) and PD-1/PD-L1 expression, it plays a role as a pr...
186 CitationsSource
Cited By9
#1Xiaoli Yin (PRC: China Medical University (PRC))
#2Lingming Kong (PRC: China Medical University (PRC))H-Index: 4
Last. Peng Liu (CMU: Carnegie Mellon University)H-Index: 10
view all 3 authors...
Background Pancreatic cancer (PC) is one of the most lethal and aggressive cancer malignancies. The lethality of PC is associated with delayed diagnosis, presence of distant metastasis, and its easy relapse. It is known that clinical treatment decisions are still mainly based on the clinical stage and pathological grade, which are insufficient to determine an appropriate treatment. Considering the significant heterogeneity of PC biological characteristics, the current clinical classificatory pat...
#1Fabio Bagante (University of Verona)H-Index: 27
#2Gaya Spolverato (UNIPD: University of Padua)H-Index: 51
Last. Timothy M. Pawlik (The Ohio State University Wexner Medical Center)H-Index: 118
view all 11 authors...
Abstract Purpose Several multi-omics classifications have been proposed for hepato-pancreato-biliary (HPB) cancers, but these classifications have not proven their role in the clinical practice and been validated in external cohorts. Patients and methods Data from whole-exome sequencing (WES) of The Cancer Genome Atlas (TCGA) patients were used as an input for the artificial neural network (ANN) to predict the anatomical site, iClusters (cell-of-origin patterns) and molecular subtype classificat...
1 CitationsSource
#1Dimitrios GiannisH-Index: 10
#2Dimitrios MorisH-Index: 18
Last. Andrew S. BarbasH-Index: 23
view all 3 authors...
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy and is associated with aggressive tumor behavior and poor prognosis. Most patients with PDAC present with an advanced disease stage and treatment-resistant tumors. The lack of noninvasive tests for PDAC diagnosis and survival prediction mandates the identification of novel biomarkers. The early identification of high-risk patients and patients with PDAC is of utmost importance. In addition, the identification of mol...
2 CitationsSource
#1Davide Melisi (University of Verona)H-Index: 31
#2Do-Youn Oh (Seoul National University Hospital)H-Index: 56
Last. Rocio Garcia-CarboneroH-Index: 28
view all 19 authors...
Background We assessed the safety, efficacy, and pharmacokinetics of the transforming growth factor beta (TGFβ) receptor inhibitor galunisertib co-administered with the anti-programmed death-ligand 1 (PD-L1) antibody durvalumab in recurrent/refractory metastatic pancreatic cancer previously treated with ≤2 systemic regimens. Methods This was a two-part, single-arm, multinational, phase Ib study. In a dose-finding phase, escalating oral doses of galunisertib were co-administered on days 1–14 with...
9 CitationsSource
#1Quan Liu (JNU: Jinan University)H-Index: 7
#2Yanhong Duo (KI: Karolinska Institutet)H-Index: 9
Last. Yihai Cao (KI: Karolinska Institutet)H-Index: 99
view all 13 authors...
Abstract Therapeutic targeting of the immune system, including chimeric antigen receptor-T cell therapy, immune checkpoint blockade therapy, neoantigen vaccines, and small molecule modulators emerges as one of the most effective therapeutic modalities for treating various cancers in human patients. However, clinical efficacies of these immunotherapeutics are generally modest and only a minority of cancer patients benefit from immunotherapy. Further, broad adverse effects, lack of reliable biomar...
7 CitationsSource
#1Chiara BazzichettoH-Index: 9
#2Claudio LuchiniH-Index: 31
Last. Michele Milella (University of Verona)H-Index: 50
view all 11 authors...
To date, pancreatic cancer is still one of the most lethal cancers in the world, mainly due to the lack of early diagnosis and personalized treatment strategies. In this context, the possibility and the opportunity of identifying genetic and molecular biomarkers are crucial to improve the feasibility of precision medicine. In 2019, the World Health Organization classified pancreatic ductal adenocarcinoma cancer (the most common pancreatic tumor type) into eight variants, according to specific hi...
5 CitationsSource
#1Francesca Simionato (University of Verona)H-Index: 14
#2Camilla Zecchetto (University of Verona)H-Index: 7
Last. Davide Melisi (University of Verona)H-Index: 31
view all 34 authors...
Background Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that often impairs postoperative treatment, and the common metastatic relapse limit the overall clinical outcomes achieved with this strategy. Polychemotherapeutic combinations are valid options for postoperative treatment in patients with good performance ...
2 CitationsSource
#1Kinga B. Stopa (Jagiellonian University)H-Index: 2
#2Agnieszka A. Kusiak (Jagiellonian University)H-Index: 3
Last. Monika A. Jakubowska (Jagiellonian University)H-Index: 9
view all 5 authors...
Pancreatic ductal adenocarcinoma (PDAC) causes annually well over 400,000 deaths world-wide and remains one of the major unresolved health problems. This exocrine pancreatic cancer originates from the mutated epithelial cells: acinar and ductal cells. However, the epithelia-derived cancer component forms only a relatively small fraction of the tumor mass. The majority of the tumor consists of acellular fibrous stroma and diverse populations of the non-neoplastic cancer-associated cells. Importan...
12 CitationsSource
#1Davide MelisiH-Index: 31
Last. Josep Tabernero (Autonomous University of Barcelona)H-Index: 118
view all 18 authors...
Purpose Galunisertib, the first small molecule transforming growth factor beta (TGFβ) receptor inhibitor, plus gemcitabine resulted in the improvement of survival in patients with unresectable pancreatic cancer, but markers to identify patients likely to respond are lacking.
28 CitationsSource